Nevirapine levels after discontinuation of rifampicin therapy and 60-week efficacy of nevirapine-based antiretroviral therapy in HIV-infected patients with tuberculosis

Clinical Infectious Diseases

Volumn 44, Issue 1, 2007, Pages 141-144

  Manosuthi, Weerawat ^a,d   Ruxrungtham, Kiat ^b   Likanonsakul, Sirirat ^a   Prasithsirikul, Wisit ^a   Inthong, Yaowarat ^a   Phoorisri, Thanongsri ^a   Sungkanuparph, Somnuek ^c  

^a MINISTRY OF PUBLIC HEALTH   (Thailand)

^b CHULALONGKORN UNIVERSITY   (Thailand)

^c MAHIDOL UNIVERSITY   (Thailand)

^d Bamrasnaradura Infectious Diseases Institute   (Thailand)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTIRETROVIRUS AGENT; ETHAMBUTOL; ISONIAZID; LAMIVUDINE; NEVIRAPINE; PYRAZINAMIDE; RIFAMPICIN; STAVUDINE;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG WITHDRAWAL; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SIDE EFFECT; TREATMENT OUTCOME; TUBERCULOSIS;

ADULT; ANTI-HIV AGENTS; ANTITUBERCULAR AGENTS; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HUMANS; MALE; NEVIRAPINE; REVERSE TRANSCRIPTASE INHIBITORS; RIFAMPIN; TREATMENT OUTCOME; TUBERCULOSIS;

EID: 33845720528     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/510078     Document Type: Article

References (15)

1. Manosuthi W, Chottanapand S, Thongyen S, Chaovavanich A, Sungkanuparph S. Survival rate and risk factors of mortality among HIV/tuberculosis-coinfected patients with and without antiretroviral therapy. J Acquir Immune Defic Syndr 2006; 43:42-6.
2. Podzamczer D, Ferrer E, Consiglio E, et al. A randomized clinical trial comparing nelfinavir or nevirapine associated to zidovudine/lamivudine in HIV-infected naive patients (the Combine Study). Antivir Ther 2002; 7:81-90.
3. Putong N, Pitisuttithum P, Supanaranond W, et al. Mycobacterium tuberculosis infection among HIV/AIDS patients in Thailand: clinical manifestations and outcomes. Southeast Asian J Trop Med Public Health 2002; 33:346-51.
4. Back D, Gibbons S, Khoo S. Pharmacokinetic drug interactions with nevirapine. J Acquit Immune Defic Syndr 2003; 34(Suppl 1):S8-14.
5. Manosuthi W, Sungkanuparph S, Thakkinstian A, et al. Plasma nevirapine levels and 24-week efficacy in HIV-infected patients receiving nevirapine-based highly active antiretroviral therapy with or without rifampicin. Clin Infect Dis 2006; 43:253-5.
6. Veen J, Raviglione M, Rieder HL, et al. Standardized tuberculosis treatment outcome monitoring in Europe: recommendations of a working group of the World Health Organization (WHO) and the European Region of the International Union Against Tuberculosis and Lung Disease (IUATLD) for uniform reporting by cohort analysis of treatment outcome in tuberculosis patients. Eur Respir J 1998; 12:505-10.
7. Ribera E, Pou L, Lopez RM, et al. Pharmacokinetic interaction between nevirapine and rifampicin in HIV-infected patients with tuberculosis. J Acquir Immune Defic Syndr 2001; 28:450-3.
8. Ramachandran G, Hemanth K, Rajasekaran S, et al. Increasing nevirapine dose can overcome reduced bioavailability due to rifampicin co-administration [abstract WePe3.3C02]. In: Program and abstracts of the 3rd International AIDS Society (IAS) Conference on HIV Pathogenesis and Treatment. Rio de Janeiro: IAS, 2005.
9. Kappelhoff BS, van Leth F, MacGregor TR, Lange J, Beijnen JH, Huitema AD. Nevirapine and efavirenz pharmacokinetics and covariate analysis in the 2NN study. Antivir Ther 2005; 10:145-55.
10. Gonzalez de Requena D, Nunez M, Jimenez-Nacher I, Soriano V. Liver toxicity caused by nevirapine. AIDS 2002; 16:290-1.
11. Ananworanich J, Moor Z, Siangphoe U, et al. Incidence and risk factors for rash in Thai patients randomized to regimens with nevirapine, efavirenz or both drugs. AIDS 2005; 19:185-92.
12. Bersoff-Matcha SJ, Miller WC, Aberg JA, et al. Sex differences in nevirapine rash. Clin Infect Dis 2001; 32:124-9.
13. Autar RS, Wit FW, Sankote J, et al. Nevirapine plasma concentrations and concomitant use of rifampin in patients coinfected with HIV-1 and tuberculosis. Antivir Ther 2005; 10:937-43.
14. Dean GL, Back DJ, de Ruiter A. Effect of tuberculosis therapy on nevirapine trough plasma concentrations. AIDS 1999; 13:2489-90.
15. Havlir D, Cheeseman SH, McLaughlin M, et al. High-dose nevirapine: safety, pharmacokinetics, and antiviral effect in patients with human immunodeficiency virus infection. J Infect Dis 1995; 171:537-45.